细胞自噬与肿瘤的发生发展及治疗

doi:10.3760/cma.j.issn.1673-422X.2018.12.009

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (12): 743-746.doi: 10.3760/cma.j.issn.1673-422X.2018.12.009

细胞自噬与肿瘤的发生发展及治疗

王鑫，宋海平，王晔，孙宏权，马学真

266042 青岛大学第二附属医院肿瘤科（王鑫、宋海平、马学真），中心实验室（王晔）；青岛市阜外心血管病医院综合内科（王鑫、孙宏权）

出版日期:2018-12-08 发布日期:2019-02-01
通讯作者: 马学真 E-mail:maxuezhen1968@126.com
基金资助:
CSCO-豪森肿瘤研究基金（Y-HS2017-059）

Autophagy in tumorigenesis and cancer therapy

Wang Xin, Song Haiping, Wang Ye, Sun Hongquan, Ma Xuezhen

Department of Oncology, Second Affiliated Hospital of Qingdao University, Qingdao 266042, China; Department of General Medicine, Qingdao Fuwai Cardiovascular Hospital, Qingdao 266034, China

Online:2018-12-08 Published:2019-02-01
Contact: Ma Xuezhen E-mail:maxuezhen1968@126.com
Supported by:
Cancer Research Foundation of CSCO-Hansoh (Y-HS2017-059)

摘要/Abstract

摘要： 细胞自噬是细胞自我更新和维持内环境稳态的重要生理过程，在肿瘤的发生发展及治疗中均发挥“双重性”作用。自噬通过保持基因组的稳定性抑制肿瘤的发生，同时又是肿瘤细胞存活的保护性机制。自噬提高抗肿瘤治疗有效性的同时又与肿瘤耐药、放射抵抗有关。在不同情况下应用自噬调控药物有望提高肿瘤细胞的治疗敏感性。

关键词: 自噬, 肿瘤, 药物疗法, 放射疗法, 靶向治疗

Abstract: Autophagy is a crucial physiological process for cellular selfrenewing and homeostasis, which plays a dual role in both tumorigenesis and antitumor treatment. It plays an antineoplastic role by maintaining genomic stability, as well as a protective role in tumorgenesis and progression. Autophagy improves the effectiveness of antitumor therapy, meanwhile, it involves in resistance of tumor cells to chemotherapy and irradiation. Using relevant autophagy regulators in different backgrounds is expected to become a new strategy for improving sensitivity of tumor cells to antitumor treatment.

Key words: Autophagy, Neoplasms, Drug therapy, Radiotherapy, Targeted therapy

王鑫，宋海平，王晔，孙宏权，马学真. 细胞自噬与肿瘤的发生发展及治疗[J]. 国际肿瘤学杂志, 2018, 45(12): 743-746.

Wang Xin, Song Haiping, Wang Ye, Sun Hongquan, Ma Xuezhen. Autophagy in tumorigenesis and cancer therapy[J]. Journal of International Oncology, 2018, 45(12): 743-746.

参考文献

［1］ Giampieri F, Afrin S, ForbesHernandez TY, et al. Autophagy in human health and disease: novel therapeutic opportunities［J］. Antioxid Redox Signal, 2018, In press. DOI: 10.1089/ars.2017.7234. ［2］ Di Fazio P, Matrood S. Targeting autophagy in liver cancer［J］. Transl Gastroenterol Hepatol, 2018, 3: 39. DOI: 10.21037/tgh.2018.06.09. ［3］ Vigen RA, Kodama Y, Viset T, et al. Immunohistochemical evidence for an impairment of autophagy in tumorigenesis of gastric carcinoids and adenocarcinomas in rodent models and patients［J］. Histol Histopathol, 2013, 28(4): 531542. DOI: 10.14670/HH28.531. ［4］ Cai J, Li R, Xu X, et al. CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy［J］. Nat Cell Biol, 2018, 20(4): 465478. DOI: 10.1038/s4155601800658. ［5］ Zhai H, Fesler A, Ba Y, et al. Inhibition of colorectal cancer stem cell survival and invasive potential by hsamiR1405p mediated suppression of Smad2 and autophagy［J］. Oncotarget, 2015, 6(23): 1973519746. DOI: 10.18632/oncotarget.3771. ［6］ Han H, Li J, Feng X, et al. Autophagyrelated genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells［J］. Oncotarget, 2017, 8(32): 5335253365. DOI: 10.18632/oncotarget.18410. ［7］ Chiu HW, Yeh YL, Wang YC, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo［J］. PLoS One, 2013, 8(10): e76340. DOI: 10.1371/journal.pone.0076340. ［8］ Palumbo S, Pirtoli L, Tini P, et al. Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments［J］. J Cell Biochem, 2012, 113(7): 23082318. DOI: 10.1002/jcb.24102. ［9］ Nguyen TL, Nokin MJ, Egorov M, et al. mTOR inhibition via displacement of phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells［J］. Cancer Res, 2018, 78(18): 53845397. DOI: 10.1158/00085472.CAN180232. ［10］ Sulaiman A, McGarry S, Lam KM, et al. Coinhibition of mTORC1, HDAC and ESR1α retards the growth of triplenegative breast cancer and suppresses cancer stem cells［J］. Cell Death Dis, 2018, 9(8): 815. DOI: 10.1038/s4141901808117. ［11］ Park JH, Lee YR, So HS, et al. The role of autophagy induced by pemetrexed in lung adenocarcinoma cells［J］. Oncol Rep, 2014, 31(5): 23652370. DOI: 10.3892/or.2014.3071. ［12］ Li LQ, Pan D, Zhang SW, et al. Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway［J］. Eur Rev Med Pharmacol Sci, 2018, 22(11): 34023407. DOI: 10.26355/eurrev_201806_15162. ［13］ Li H, Jin X, Chen B, et al. Autophagyregulating microRNAs: potential targets for improving radiotherapy［J］. J Cancer Res Clin Oncol, 2018, 144(9): 16231634. DOI: 10.1007/s0043201826758. ［14］ Jin X, Liu Y, Ye F, et al. Role of autophagy in high linear energy transfer radiationinduced cytotoxicity to tumor cells［J］. Cancer Sci, 2014, 105(7): 770778. DOI: 10.1111/cas.12422. ［15］ Koukourakis MI, Kalamida D, Mitrakas A, et al. Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer［J］. Biochem Biophys Res Commun, 2015, 461(2): 268274. DOI: 10.1016/j.bbrc.2015.04.014. ［16］ Mo N, Lu YK, Xie WM, et al. Inhibition of autophagy enhances the radiosensitivity of nasopharyngeal carcinoma by reducing Rad51 expression［J］. Oncol Rep, 2014, 32(5): 19051912. DOI: 10.3892/or.2014.3427. ［17］ Chaachouay H, Ohneseit P, Toulany M, et al. Autophagy contributes to resistance of tumor cells to ionizing radiation［J］. Radiother Oncol, 2011, 99(3): 287292. DOI: 10.1016/j.radonc.2011.06.002. ［18］ Li H, Jin X, Chen B, et al. Autophagyregulating micrornas: potential targets for improving radiotherapy［J］. J Cancer Res Clin Oncol, 2018, 144(9): 16231634. DOI: 10.1007/s0043201826758. ［19］ Wang P, Zhang J, Zhang L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells［J］. Gastroenterology, 2013, 145(5): 11331143. e12. DOI: 10.1053/j.gastro.2013.07.048. ［20］ Zhou ZR, Yang ZZ, Wang SJ, et al. The Chk1 inhibitor MK8776 increases the radiosensitivity of human triplenegative breast cancer by inhibiting autophagy［J］. Acta Pharmacol Sin, 2017, 38(4): 513523. DOI: 10.1038/aps.2016.136. ［21］ Zheng L, Zhang Y, Liu Y, et al. MiR106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer［J］. J Transl Med, 2015, 13: 252. DOI: 10.1186/s129670150592z. ［22］ Hu JL, He GY, Lan XL, et al. Inhibition of ATG12mediated autophagy by miR214 enhances radiosensitivity in colorectal cancer［J］. Oncogenesis, 2018, 7(2): 16. DOI: 10.1038/s4138901800288. ［23］张其程, 徐克. 自噬在EGFRTKI类肿瘤靶向药物对肺癌的治疗和耐药中作用的研究进展［J］. 中国肺癌杂志, 2016, 19(9): 607614. DOI: 10.3779/j.issn.10093419.2016.09.09. ［24］ Wei Y, Zou Z, Becker N, et al. EGFRmediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance［J］. Cell, 2013, 154(6): 12691284. DOI: 10.1016/j.cell.2013.08.015. ［25］ Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells［J］. PLoS One, 2011, 6(6): e18691. DOI: 10.1371/journal.pone.0018691. ［26］ Lee JG, Wu R. Combination erlotinibcisplatin and Atg3mediated autophagy in erlotinib resistant lung cancer［J］. PLoS One, 2012, 7(10): e48532. DOI: 10.1371/journal.pone.0048532. ［27］ Huang Y, Chen Y, Mei Q, et al. Combined inhibition of the EGFR and mTOR pathways in EGFR wildtype nonsmall cell lung cancer cell lines with different genetic backgrounds［J］. Oncol Rep, 2013, 29(6): 24862492. DOI: 10.3892/or.2013.2357. ［28］ Xu Z, Hang J, Hu J, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells［J］. J BUON, 2014, 19(2): 466473.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

细胞自噬与肿瘤的发生发展及治疗

Autophagy in tumorigenesis and cancer therapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价